Search

Your search keyword '"Ligand Pharmaceuticals Inc."' showing total 154 results
Start Over Descriptor "Ligand Pharmaceuticals Inc." Journal pharma business week
154 results on '"Ligand Pharmaceuticals Inc."'

1. Ligand Pharmaceuticals Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)]: (Nov. 8, 2024).

Subjects
CORPORATE finance, UNAUDITED financial statements, PHARMACEUTICAL biotechnology industry, BIOTECHNOLOGY industries, INDUSTRY classification
Abstract

Ligand Pharmaceuticals Inc. recently filed a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) on November 8, 2024. This filing is a quarterly report that provides unaudited financial statements and offers insight into the company's financial position throughout the year. The Form 10-Q must be submitted for the first three fiscal quarters within 45 days of the quarter's end. The SEC filing is a formal document or financial statement required by publicly-traded companies, and more information can be found on the SEC's website. [Extracted from the article]

Published
2024

2. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Sept. 18, 2024).

Subjects
PHARMACEUTICAL biotechnology industry, BIOTECHNOLOGY industries, INDUSTRY classification, PUBLIC companies, FINANCIAL statements
Abstract

Ligand Pharmaceuticals Inc., a biopharmaceutical company, has filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on September 18, 2024. The form is a statement of changes in beneficial ownership of securities. The company's contact information is provided, and the filing is in accordance with SEC regulations that require directors, officers, and owners of more than ten percent of a class of equity securities to report their ownership. The filing can be found on the SEC's website. [Extracted from the article]

Published
2024

3. Ligand Pharmaceuticals Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405]: (Feb. 29, 2024).

Subjects
CORPORATION reports, DRUGS, PHARMACEUTICAL biotechnology industry, BIOTECHNOLOGY industries
Abstract

Ligand Pharmaceuticals Inc., a biopharmaceutical company, has filed a Form 10-K with the U.S. Securities and Exchange Commission (SEC). The filing provides a comprehensive overview of the company's business and must be submitted within 90 days after the end of the fiscal year. The contact information for Ligand Pharmaceuticals Inc. is provided in the filing. This news article is a factual report and does not express any judgments or opinions. [Extracted from the article]

Published
2024

4. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Sept. 25, 2023).

Subjects
SECURITIES, DRUGS, BIOTECHNOLOGY industries, INDUSTRY classification
Abstract

Ligand Pharmaceuticals Inc., a biopharmaceutical company, filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on September 25, 2023. The filing is a statement of changes in beneficial ownership of securities. The company's contact information is provided, and additional information about Form 4 is explained. A SEC filing is a formal document or financial statement submitted by publicly-traded companies. For more information on this filing, readers can visit the provided SEC link. [Extracted from the article]

Published
2023

10. Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging

Subjects
Ligand Pharmaceuticals Inc., Intellectual property, Pharmaceutical industry, Intellectual property, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2018 JAN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces initiation of a program to develop contrast agents [...]

Published
2018

11. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jan. 11, 2018)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2018 JAN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2018

12. Reminder: Ligand to Host Analyst Day on November 14th in New York City

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 NOV 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, [...]

Published
2017

13. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Aug. 25, 2017)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2017

14. Ligand Pharmaceuticals Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities: (Aug. 22, 2017)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2017

15. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Aug. 22, 2017)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2017

16. Ligand's Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ Delafloxacin for Acute Bacterial Skin and Skin Structure Infections ABSSSI

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Bacterial infections -- Drug therapy -- Health aspects, Staphylococcus aureus -- Health aspects, Disease susceptibility -- Drug therapy -- Health aspects, Infection -- Drug therapy -- Health aspects, Skin -- Health aspects, Pharmaceutical industry -- Health aspects, Antibacterial agents -- Health aspects, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that partner Melinta Therapeutics, a privately held company [...]

Published
2017

17. Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it will receive $10 million from a contractually [...]

Published
2017

18. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (May. 26, 2017)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2017

19. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals (Jan. 12, 2017)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 JAN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2017

20. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Dec. 29, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2017

21. Ligand Enters Commercial License and Supply Agreements for Captisol[R]-enabled trametinib

Subjects
Ligand Pharmaceuticals Inc., Novartis AG, Pharmaceutical industry, Melanoma, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2017 JAN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into global license and supply [...]

Published
2017

22. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 25, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 DEC 12 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

23. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 18, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 DEC 5 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

24. Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Bacterial infections -- Drug therapy -- Health aspects, Staphylococcus aureus -- Health aspects, Cross infection -- Drug therapy -- Health aspects, Skin -- Health aspects, Pharmaceutical industry -- Health aspects, Drug approval -- Health aspects, Antibacterial agents -- Health aspects, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 NOV 7 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Melinta Therapeutics, a privately held company developing novel [...]

Published
2016

25. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Sept. 23, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

26. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Sept. 9, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

27. Ligand Pharmaceuticals Inc. Files SEC Form 4/A, Statement of Changes in Beneficial Ownership of Securities (Sept. 9, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

28. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Sept. 6, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

29. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Jul. 26, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

30. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Jul. 19, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

31. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals (Jul. 8, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

32. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 5, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

33. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Jun. 9, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 JUN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

34. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (May. 3, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

35. Ligand Pharmaceuticals Inc : Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Mar. 9, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 MAR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

36. Ligand Pharmaceuticals Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405] (Feb. 26, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 MAR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

37. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Jan. 15, 2016)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 FEB 1 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2016

38. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Dec. 9, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

39. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 13, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

40. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Aug. 28, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

41. FDA Expands Use of Promacta[R] to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia

Subjects
Ligand Pharmaceuticals Inc., Novartis AG, Thrombocytopenia -- Care and treatment, Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health, Promacta (Medication)
Abstract

2015 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the FDA has approved an expanded use [...]

Published
2015

42. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 14, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

43. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals [Amend] (Jul. 2, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 JUL 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

44. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 24, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 JUL 6 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

45. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 11, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2015 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2015

46. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (May. 14, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing [...]

Published
2015

47. Ligand Pharmaceuticals Inc. Files SEC Form SC 13D, General Statement of Acquisition of Beneficial Ownership (May. 8, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing [...]

Published
2015

48. Ligand Pharmaceuticals Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (May. 7, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing [...]

Published
2015

49. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Mar. 20, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing [...]

Published
2015

50. Ligand Pharmaceuticals Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material (Mar. 13, 2015)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Proxy, Securities law, Pharmaceutical industry, Independent regulatory commissions, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results